Higher Number of Tumor-Infiltrating PD-L1+ Cells Is Related to Better Response to Multikinase Inhibitors in Hepatocellular Carcinoma

Multikinase inhibitors (MKIs) such as sorafenib and lenvatinib are first-line treatments for unresectable hepatocellular carcinoma (HCC) and are known to have immunomodulatory effects. However, predictive biomarkers of MKI treatment in HCC patients need to be elucidated. In the present study, thirty...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Ji Won, Kim, Ji Hoon, Kim, Dong Hyun, Jang, Jeong Won, Bae, Si Hyun, Choi, Jong Young, Yoon, Seung Kew, Ahn, Jaegyoon, Yang, Hyun, Sung, Pil Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138027/
https://www.ncbi.nlm.nih.gov/pubmed/37189554
http://dx.doi.org/10.3390/diagnostics13081453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138027/
https://www.ncbi.nlm.nih.gov/pubmed/37189554
http://dx.doi.org/10.3390/diagnostics13081453

Ejemplares similares